Rezolute (RZLT) Stock Forecast & Price Target

Rezolute is attractive because its lead asset, ersodetug, is addressing refractory hypoglycemia in hyperinsulinism with a focused, hospital-based endpoint that is less vulnerable to behavioral confounding than the earlier sunRIZE experience. In upLIFT, seven responders among the first eight patients have already been disclosed, leaving the study only two responses away from the approximately nine of sixteen needed for statistical success, while all six patients who completed the pivotal period continued into OLE with no drug-related safety signals. That combination of de-risked efficacy, clean tolerability, and a potential YE26 topline readout ahead of a mid-2027 BLA filing supports a favorable fundamental view of the company’s rare-disease commercial opportunity.

Rezolute is a clinical-stage biotechnology company with no revenue, making its valuation highly dependent on future clinical and regulatory success rather than current operating performance. Its lead asset, ersodetug, still faces meaningful uncertainty because upLIFT must meet its primary endpoint, the FDA may require additional congenital HI studies, and EU congenital HI was removed from the valuation due to approvability concerns and limited visibility on the European regulatory strategy. Even with improved confidence in tumor HI and a revised 2036 discounted risk-adjusted revenue estimate of $1.3B, the company remains exposed to commercialization, manufacturing, and financing dilution risks, and it will likely need additional capital.